TY - JOUR
T1 - The antinociceptive properties of reboxetine in acute pain
AU - Schreiber, Shaul
AU - Frishtick, Ruthi
AU - Volis, Ina
AU - Rubovitch, Vardit
AU - Pick, Chaim G.
AU - Weizman, Ronit
N1 - Funding Information:
Dr. Schreiber and Dr. Pick were supported by The Dr. Miriam and Sheldon G. Adelson Center for the Biology of Addictive Diseases at Tel-Aviv University.
PY - 2009/10
Y1 - 2009/10
N2 - The antinociceptive effects of the selective noradrenaline reuptake inhibitor antidepressant reboxetine and its interaction with various opioid and noradrenaline receptor subtypes were evaluated. Reboxetine (i.p.) induced a weak dose-dependent antinociceptive effect in acute pain, using the hotplate model. The reboxetine-induced antinociception was significantly inhibited by the opioid receptor antagonists naloxone, nor-BNI, naltrindole and b-FNA, implying a non-selective role for the opioid receptors in the reboxetine's antinociceptive effect. The adrenergic antagonists yohimbine and phentolamine attenuated to some extent the reboxetine-induced antinociception, implying a minor adrenergic mechanism of antinociception. The addition of opioid or α2 agonists, did not potentiate the antinociception effect of reboxetine. Thus, it seems that reboxetine possesses a weak antinociceptive effect, mediated by non-selective opioid receptors and influenced somewhat by noradrenaline α2 receptors. These results suggest that reboxetine as monotherapy does not have sufficient efficacy in the management of acute pain. However, further research is needed in order to establish its possible use alone or in combination with other antidepressants or analgesics in the amelioration of chronic pain disorders.
AB - The antinociceptive effects of the selective noradrenaline reuptake inhibitor antidepressant reboxetine and its interaction with various opioid and noradrenaline receptor subtypes were evaluated. Reboxetine (i.p.) induced a weak dose-dependent antinociceptive effect in acute pain, using the hotplate model. The reboxetine-induced antinociception was significantly inhibited by the opioid receptor antagonists naloxone, nor-BNI, naltrindole and b-FNA, implying a non-selective role for the opioid receptors in the reboxetine's antinociceptive effect. The adrenergic antagonists yohimbine and phentolamine attenuated to some extent the reboxetine-induced antinociception, implying a minor adrenergic mechanism of antinociception. The addition of opioid or α2 agonists, did not potentiate the antinociception effect of reboxetine. Thus, it seems that reboxetine possesses a weak antinociceptive effect, mediated by non-selective opioid receptors and influenced somewhat by noradrenaline α2 receptors. These results suggest that reboxetine as monotherapy does not have sufficient efficacy in the management of acute pain. However, further research is needed in order to establish its possible use alone or in combination with other antidepressants or analgesics in the amelioration of chronic pain disorders.
KW - Antidepressants
KW - Antinociception
KW - Hotplate
KW - Noradrenaline
KW - Opioid receptor subtypes
KW - Pain
KW - Reboxetine
UR - http://www.scopus.com/inward/record.url?scp=69049112766&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2009.06.004
DO - 10.1016/j.euroneuro.2009.06.004
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:69049112766
SN - 0924-977X
VL - 19
SP - 735
EP - 739
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 10
ER -
